Volume 87 Issue 1 | p. 14 | Concentrates
Issue Date: January 5, 2009

AstraZeneca, MAP In Asthma Drug Pact

Department: Business

AstraZeneca has linked with MAP Pharmaceuticals to develop a nebulized formulation of budesonide, a potential pediatric asthma treatment in Phase III trials. MAP will get $40 million upfront. It could also reap $35 million if the drug achieves its safety and efficacy goals in the Phase III trials and could gain up to $240 million in other milestone payments. The asthma drug uses Elan's NanoCrystal technology to achieve the small and stable particles that enable delivery through nebulization.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment